Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Shifa Biomedical presents data on new PCSK9 inhibitor P-21

Nov. 15, 2018

Celgene patents GLP-1 receptor agonists

Nov. 14, 2018

KalVista designs enlarged phase II study for KVD-900 in HAE

Nov. 13, 2018

Small-molecule hepcidin production inhibitor developed for treatment of anemia of chronic disease

Nov. 12, 2018

Codexis announces topline results from phase Ia study of CDX-6114

Nov. 9, 2018

Study points to new bone building strategy

Nov. 9, 2018

DSMB recommends discontinuation of phase III study of PREOB for osteonecrosis

Nov. 7, 2018

Corcept Therapeutics enrolling participants in phase III study of relacorilant

Nov. 7, 2018

Fat and fibroblasts

Nov. 7, 2018

REWIND study of Trulicity meets primary efficacy objective

Nov. 6, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...